Frequency of Fabry disease in male and female haemodialysis patients in Spain

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Gaspar, Paulo ^a   Herrera, Julio ^b   Rodrigues, Daniel ^a   Cerezo, Sebastián ^c   Delgado, Rodrigo ^d   Andrade, Carlos F ^d   Forascepi, Ramón ^e   Macias, Juan ^f   del Pino, Maria D ^g   Prados, Maria D ^c   de Alegria, Pilar R ^h   Torres, Gerardo ⁱ   Vidau, Pedro ^b   Sá Miranda, Maria C ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL DE CABUEÑES   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g HOSPITAL TORRECÁRDENAS   (Spain)

^h Servicio de Nefrologia   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALPHA GALACTOSIDASE; ARGININE; ASPARTIC ACID; CYSTEINE; GLYCINE; TYROSINE; VALINE;

ADULT; AGED; ALLELE; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; GENE MUTATION; GENOTYPE; HEART DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DYSFUNCTION; MALE; NUCLEOTIDE SEQUENCE; SPAIN; SYMPTOM; AMINO ACID SUBSTITUTION; ENZYMOLOGY; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; MUTATION; PHENOTYPE; RENAL REPLACEMENT THERAPY;

ADULT; AGED, 80 AND OVER; ALLELES; ALPHA-GALACTOSIDASE; AMINO ACID SUBSTITUTION; FABRY DISEASE; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; RENAL DIALYSIS; SPAIN;

EID: 77949891815     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-19     Document Type: Article

References (25)

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: FD. The metabolic and molecular basis of inherited disease 2001, 3733-3774. McGraw-Hill, New York, USA, Scriver CR, Beaud Sly WS, Valle D, Kinzler KE, Vogelstein B.
2. Schiffmann R. FD. Pharmacol Ther 2009, 122(1):65-77. 10.1016/j.pharmthera.2009.01.003, 19318041.
3. Maier EM, Osterrieder S, Whybra C, et al. Disease manifestations and X inactivation in heterozygous females with FD. Acta Paediatr Suppl 2006, 95:30-38. 10.1080/08035320600618809, 16720462.
4. Fukushima M, Tsuchiyama Y, Nakato T, et al. A female heterozygous patient with Fabry's disease with renal accumulation of trihexosylceramide detected with a monoclonal antibody. Am J Kidney Dis 1995, 26:952-955. 10.1016/0272-6386(95)90061-6, 7503071.
5. Elleder M, Bradová V, Smíd F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990, 417:449-455. 10.1007/BF01606034, 2173254.
6. Von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991, 324:395-399.
7. Nagao Y, Nakashima H, Fukuhara Y, et al. Hypertrophic cardiomyopathy in late-onset variant of FD with high residual activity of α-galactosidase A. Clin Genet 1991, 39:233-237.
8. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995, 333:288-293. 10.1056/NEJM199508033330504, 7596372.
9. Sessa A, Meroni M, Battini G, Righetti M, Mignani R. Chronic renal failure, dialysis, and renal transplantation in Anderson-FD. Semin Nephrol 2004, 24:532-536. 10.1016/j.semnephrol.2004.06.024, 15490423.
10. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254. 10.1001/jama.281.3.249, 9918480.
11. Pinto R, Caseiro C, Lemos M, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004, 12:87-92. 10.1038/sj.ejhg.5201044, 14685153.
12. Shelley ED, Shelley WB, Kurczynski TW. Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of FD. Pediatr Dermatol 1995, 12:215-219. 10.1111/j.1525-1470.1995.tb00161.x, 7501549.
13. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset FD revealed by newborn screening. Am J Hum Genet 2006, 79:31-40. 10.1086/504601, 1474133, 16773563.
14. Nakao S, Kodama C, Takenaka T, et al. FD: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003, 64:801-807. 10.1046/j.1523-1755.2003.00160.x, 12911529.
15. Kotanko P, Kramar R, Devrnja D, et al. Results of a nationwide screening for Anderson-FD among dialysis patients. J Am Soc Nephrol 2004, 15:1323-1329. Erratum in: J Am Soc Nephrol 2004; 15: 1a. J Am Soc Nephrol 2004; 15: A4, 10.1097/01.ASN.0000124671.61963.1E, 15100373.
16. Merta M, Reiterova J, Ledvinova J, Poupetová H, Dobrovolny R, Rysavá R, Maixnerová D, Bultas J, Motán J, Slivkova J, Sobotova D, Smrzova J, Tesar V. A nationwide blood spot screening study for FD in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 2007, 22(1):179-86. 10.1093/ndt/gfl528, 17040996.
17. Monserrat L, Gimeno-Blanes JR, Marín F, et al. Prevalence of FD in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007, 50:2399-2403. 10.1016/j.jacc.2007.06.062, 18154965.
18. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the α-galactosidase A gene that cause FD. Am J Hum Genet 1993, 53:1186-1197. 1682507, 7504405.
19. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. FD: D313Y is an α-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 2003, 80:307-314. 10.1016/S1096-7192(03)00136-7, 14680977.
20. Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006, 113:2697-2705. 10.1161/CIRCULATIONAHA.105.593558, 16754800.
21. Morais P, Santos AL, Baudrier T, Mota AV, Oliveira JP, Azevedo F. Angiokeratomas of Fabry successfully treated with intense pulsed light. J Cosmet Laser Ther 2008, 10(4):218-22. 10.1080/14764170802275832, 18830871.
22. Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ. FD: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 2003, 22(6):486-92. 10.1002/humu.10275, 14635108.
23. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ. Hollak CE Screening for FD in high risk populations: a systematic review. J Med Genet 2009,
24. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Α-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973, 81:157-171.
25. Shabbeer J, Robinson M, Desnick RJ. Detection of α-galactosidase a mutations causing FD by denaturing high performance liquid chromatography. Hum Mutat 2005, 25:299-305. 10.1002/humu.20144, 15712228.